A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand osteoarthritis – The HUMOR trial
Osteoarthritis and Cartilage Mar 04, 2018
Aitken D, et al. - This randomized was conducted to evaluate the effectiveness of adalimumab in cases with erosive hand osteoarthritis (OA). In patients with erosive hand OA with MRI-detected synovitis, adalimumab did not show any effect on pain, synovitis or bone marrow lesions (BMLs) as compared to placebo after 12 weeks.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
